Praxis Precision Medicines IncPraxis Precision Medicines Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Full Sustainability analysis of Praxis Precision Medicines Inc can be reached by signing up for free. Other companies in the rating industry group for Praxis Precision Medicines Inc are shownin the table. If you work at Praxis Precision Medicines Inc and you wish to use your ESG aseessment, please get in touch.

Praxis Precision Medicines Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 1.6, social score of 1.6 and governance score of 5.3.

SDG Transparency Score for Praxis Precision Medicines Inc 

3.0

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Praxis Precision Medicines Inc 
1.6

Environmental

1.6

Social

5.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1760Protagenic Therapeutics Inc
3.1
Medium
1760Vcanbio Cell & Gene Engineering Corp Ltd
3.1
Medium
1800Praxis Precision Medicines Inc
3.0
Medium
1800Allergan plc
3.0
Medium
1800Aptevo Therapeutics Inc
3.0
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Praxis Precision Medicines Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc offer flexible work?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose water use targets?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Praxis Precision Medicines Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Praxis Precision Medicines Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Praxis Precision Medicines Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose its waste policy?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose energy use targets?

LockedSign up for free to unlock

Does Praxis Precision Medicines Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Praxis Precision Medicines Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Praxis Precision Medicines Inc
These potential risks are based on the size, segment and geographies of the company.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Sorry!

Failed to process!